Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Prophylaxis Against Invasive Fungal Disease for Neutropenic Children and Young Adults—Reply

Prophylaxis Against Invasive Fungal Disease for Neutropenic Children and Young Adults—Reply Letters employed by the funding institution who are included as authors or in the participants diagnosed at 65 years or older. There was no acknowledgments. trend by age for PV prevalence in BRCA1/2 (P = .34) or other Meeting Presentation: Preliminary results were presented in partial form at breast cancer–associated genes (P =.54) (Table 2). the American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 2019. Discussion | In this study, 3.55% of unselected, postmeno- Additional Contributions: We thank Krystal Brown, PhD, Maria Elias, PhD, pausal patients with breast cancer carried PVs in breast Anne-Renee Hartman, MD, (currently employed by GRAIL Inc), Elisha Hughes, PhD, Jonathan Lancaster, MD, PhD, Eric Rosenthal, PhD, ScM, and Nanda Singh, cancer–associated genes, a 3-fold higher prevalence than PhD, Myriad Genetics; Kathy Pan, MD, Los Angeles Biomedical Institute at among cancer-free control participants and without decrease Harbor-UCLA; Lihong Qi, PhD, University of California, Davis; Kerryn Reding, by age. Women diagnosed when younger than 65 years had PhD, Fred Hutchinson Cancer Research Center and University of Washington; similar probability of BRCA1/2 PVs as Ashkenazi Jewish indi- and Jean Tang, MD, PhD, Stanford University; for their assistance in assay performance and analysis, preparation, and critical http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Prophylaxis Against Invasive Fungal Disease for Neutropenic Children and Young Adults—Reply

JAMA , Volume 323 (10) – Mar 10, 2020

Loading next page...
 
/lp/american-medical-association/prophylaxis-against-invasive-fungal-disease-for-neutropenic-children-okWrJSozGP

References (7)

Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2020.0175
Publisher site
See Article on Publisher Site

Abstract

Letters employed by the funding institution who are included as authors or in the participants diagnosed at 65 years or older. There was no acknowledgments. trend by age for PV prevalence in BRCA1/2 (P = .34) or other Meeting Presentation: Preliminary results were presented in partial form at breast cancer–associated genes (P =.54) (Table 2). the American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 2019. Discussion | In this study, 3.55% of unselected, postmeno- Additional Contributions: We thank Krystal Brown, PhD, Maria Elias, PhD, pausal patients with breast cancer carried PVs in breast Anne-Renee Hartman, MD, (currently employed by GRAIL Inc), Elisha Hughes, PhD, Jonathan Lancaster, MD, PhD, Eric Rosenthal, PhD, ScM, and Nanda Singh, cancer–associated genes, a 3-fold higher prevalence than PhD, Myriad Genetics; Kathy Pan, MD, Los Angeles Biomedical Institute at among cancer-free control participants and without decrease Harbor-UCLA; Lihong Qi, PhD, University of California, Davis; Kerryn Reding, by age. Women diagnosed when younger than 65 years had PhD, Fred Hutchinson Cancer Research Center and University of Washington; similar probability of BRCA1/2 PVs as Ashkenazi Jewish indi- and Jean Tang, MD, PhD, Stanford University; for their assistance in assay performance and analysis, preparation, and critical

Journal

JAMAAmerican Medical Association

Published: Mar 10, 2020

There are no references for this article.